1. Academic Validation
  2. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34

HIV-1 resistance to the gp41-dependent fusion inhibitor C-34

  • Antiviral Res. 2003 Jul;59(2):137-42. doi: 10.1016/s0166-3542(03)00071-8.
Mercedes Armand-Ugón 1 Arantxa Gutiérrez Bonaventura Clotet José A Esté
Affiliations

Affiliation

  • 1 Hospital Germans Trias i Pujol, Universitat Autónoma de Bercelona, 08916 Badalona, Spain.
Abstract

The gp41 subunit of HIV-1 has been recently recognized as a target for Antiviral therapy. C-34 is a peptide that mimics the heptad repeat 2 in the ectodomain of gp41. Here, we describe two HIV-1 strains selected after 5 and 17 passages in culture with increasing concentrations of C-34 (breakthrough concentration of 10 microg/ml). The HXB2-derived strain was more than 1000-fold resistant and contained a V38E mutation in the gp41 coding DNA sequence. The NL4-3-derived strain was more than 500-fold resistant and contained a L33S mutation in gp41. No cross-resistance to the RT inhibitor AZT, the HIV binding inhibitor dextran sulfate (DS), or the Chemokine Receptor antagonist ALX-40-4C was detected. These data indicate that HIV-1 can overcome C-34 inhibition through mutations at residues not involved in the formation of the hydrophobic cavity of gp41.

Figures
Products